Effects of Salmeterol-Fluticasone Combined with Treprostinil on Blood Gas Indices and Inflammatory Factors in Patients with COPD Complicated with Severe Pulmonary Hypertension

Abstract

Background: To analyze the effects of Salmeterol-Fluticasone combined with treprostol on blood gas indexes and inflammatory factors in patients with chronic obstructive pulmonary disease (COPD) complicated with severe pulmonary hypertension. Methods: A total of 108 patients with COPD complicated with severe pulmonary hypertension admitted to our hospital from May 2019 to April 2022 were selected and divided into control group and study group by random number table method, with 54 cases in each group. Both groups were given low flow oxygen therapy, the control group was given treprostinil, and the observation group was given Salmeterol-Fluticasone and treprostinil. The clinical efficacy, blood gas index, serum factor level and incidence of adverse reactions were compared between the two groups. Results: After treatment, the total clinical effective rate of observation group was significantly higher than that of control group. Compared with those before treatment, arterial partial pressure of oxygen (PaO₂) and blood oxygen saturation (SaO₂) levels in two groups after treatment were significantly increased, and the levels of PaO₂ and SaO₂ in observation group were significantly higher than those in the control group (p < 0.05). Compared with those before treatment, the levels of arterial blood partial pressure of carbon dioxide (PaCO₂), serum matrix metalloproteinase-9 (MMP-9), C-reactive protein (CRP) and tumor necrosis factor (TNF-α) in two groups after treatment were significantly decreased, and the levels in the observation group were significantly lower than those in the control group (p < 0.05). There was no significant difference in the incidence of adverse reactions between two groups (p > 0.05). Conclusion: Salmeterol-Fluticasone combined with treprostinil has excellent efficacy in the treatment of COPD patients with severe pulmonary hypertension, which can not only effectively improve the hypoxia of patients, but also help to relieve the inflammatory response of the body, and has a high safety.